KRAS mutation is one of the most prevalent driver mutations in NSCLC, especially the KRAS G12C mutation, which is continuously activated via the RAS-MAPK signaling pathway and promotes the proliferation and survival of tumor cells. Here, KRAS is linked to neoplasm.